MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or ...
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
Cure Today1 小时
FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment
Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...
Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients ...
marketinference1 小时
Janux Therapeutics Reports Positive Clinical Data
Janux Therapeutics' pipeline includes janx007, a tumor-activated T cell engager (TRACT) that targets prostate-specific ...
News Medical1 天
How Dysregulated Cell Signaling Causes Disease
Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...
centerforbiosimilars6 天
Retrospective Study Shows Bevacizumab Biosimilar Efficacy in NSCLC
Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...
He's a doctor studying why lung cancer rates are rising in Asian Americans with no smoking ...
Stanford University medical professor Dr. Bryant Lin was diagnosed with stage IV lung cancer despite never smoking. Now, he's ...
The Brighterside of News on MSN3 天
Cutting-edge discovery looks to transform type 1 diabetes, cancer and autoimmune disease care
Regenerative medicine has the potential to reshape how we treat diseases, offering new hope for patients requiring cell, ...
manilatimes5 天
Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab ...
Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...
Pharmabiz4 天
China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab
China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab: Hong Kong Friday, November 29, 2024, 10:00 Hrs [IST] Akeso, Inc., a leading biopharmace ...